OSP was delighted to talk to Vetter’s Carsten Press, a senior leader of the global sales organization, and business development among many operational functions.
Provider of pharmaceutical and nutraceutical ingredients, Roquette, is excited to unveil its extensive range of excipients for moisture protection at CPHI Barcelona next week.
The increasing prevalence of chronic diseases could see the market for active pharmaceutical ingredients (APIs) growing by 7.5% per year, says a report by Prophecy Market Insights.
Multinational pharmaceutical company, Gedeon Richter UK Ltd, announced this week that it has acquired full marketing and distribution rights to a contraceptive range.
Neuraxapharm Group, a European-based pharmaceutical company that focuses on central nervous system (CNS) announced last week that it had signed a binding agreement to divest API developer and manufacturer company, Inke, to private equity manager Keensight...
An expert from the company discusses how ever-changing patient needs and other dynamic factors are likely to impact pharma ingredient trends down the road.
The synthetic biology company which specializes in producing ingredients for plant-inspired medicines has a pilot-scale manufacturing facility in the works.
A company leader advises that the growing need for high-potency active pharmaceutical ingredients calls for CDMOs that consistently deliver quality at scale.
This month’s announcements of appointments, partnerships, expansions, and mergers include Curia, Thread, TFF Pharmaceuticals, and other notable companies.
The contract development and manufacturing organization plans to invest €7.3m to expand and upgrade API production capacity at its Mourenx, France facility.
The union of the active pharmaceutical ingredient supplier and contract development and manufacturing organization will create a global services company.
The CPhI Worldwide exhibitor will show Syloid XDP, a silica carrier designed to convert liquid, waxy, or oily active ingredients into free-flowing powders.
BASF has announced plans for a specialty amines plant at its site on the Nanjing Chemical Industry Park in China, citing increasing demand from customers in Asia.
The European Commission has confirmed that UK drug ingredient manufacturers will have to supply European customers with written confirmation their products are made in compliance with EU standards after Brexit.
Former J&J controlled substance API unit Noramco is to rejig its business to cater for branded and generic drug firms and companies looking for formulation tech solutions.
The Pharma & Biopharma Outsourcing Association (PBOA) has helped negotiate reduced fees for CMOs in the FDA’s proposed reauthorisation of the Generic Drug User Fee Amendment (GDUFA).
Siegfried Holding AG has attributed a surge in API sales to the drug ingredients business it bought from BASF last year, but says that integration costs hurt profits.
The US FDA has banned Phalanx Labs from shipping products to the US after the Indian API and intermediates firm refused to let inspectors visit its site in Visakhapatnam.
Xellia Pharmaceuticals has started building a stability and release-testing unit at its API facility in Budapest, Hungary that is designed to support increased output.
Indian drug and API importers can apply for licenses online through a new service launched by the Central Drugs Standards Control Organisation (CDSCO).
The annual announcement of FDA user fees has brought scrutiny on the price tag for generic drug applications, as the approval backlog is almost a year longer than in 2012.
Canada has asked importers to quarantine APIs made by India’s Polydrug Laboratories over concerns about its manufacturing plant in Ambarnath in Maharashtra.
BASF says it remains committed to the pharma industry despite plans to divest its custom synthesis business and around 100 APIs and intermediates to Siegfried Holding.
Ranbaxy has reported a 14% drop year-on-year of overseas revenues attributed in part to the voluntary suspension of shipments from its Toansa and Dewas facilities API facilities.
Swiss high potency active pharmaceutical ingredient (API) contractor Cerbios has broken ground on a building that will bring together its chemical and biological R&D departments.
Europe could face drug shortages if the US is not granted exemption from new API import requirements, according to a US chemical industry trade association.
Inspections in countries not expected to confirm API quality or seek exemption from new EU import regs “cannot be seen as a solution” to shortage concerns says the MHRA.
